Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)
About the study
The purpose of this registry study is to gather effectiveness, QoL, safety and procedural information on TheraSphere® for the treatment of participants with Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (iCC) and liver metastases for colon cancer (mCRC) in real world clinical practice settings in France.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
EXCLUSION CRITERIA
- Participant has received a reimbursed dose of TheraSphere®
- Participant does not oppose to the collection of his/her medical personal data
Exclusion:
- Participant has opposed to data collection
- Participant has not received a reimbursed dose of TheraSphere® (free of charge dose)
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Hepatocellular Carcinoma
Age (in years)
18+
Participants needed
500
Est. Completion Date
Jan 1, 2025
Treatment type
Observational [Patient Registry]
Sponsor
Boston Scientific Corporation
ClinicalTrials.gov identifier
NCT04069468
Study number
BTG-007996-01
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?